Phase 3 N=69 A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced Cancer
Neoplasms
Primary: On-Study Duration of Trial Treatment — 386.0 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=27 A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa
Parkinson's Disease
Primary: Pharmacokinetics Measurements to Determine Cmax for Carbidopa (CD) and Levodopa (LD) Plasma Concentrations From Samples Collected Pre-dose and at Different Time Points…
Phase 3 N=14 Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations
Carcinoma, Non-Small-Cell Lung
Primary: Safety Assesment — 92.9; 35.7; 35.7; 21.4 Percentage of participants
Phase 2 N=32 Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer
Pancreatic Cancer · Adenocarcinoma of the Pancreas
Primary: Time to Tumor Progression — 3.5 months
Phase 4 N=88 Study of the Durability of Glycemic Control With Nateglinide
Type 2 Diabetes Mellitus
Primary: The Durability of Nateglinide in Comparison With Those of Glimepiride Based on the Withdrawal Rate — 10; 7 Participants
Phase 3 N=33 Effect of Vitamin D Supplementation on Exercise Adaptations in Patients on Statin Therapy
Dyslipidemias
Primary: Peak Oxygen Consumption — 43.8; 51.6; 53.5 percentage of predicted value
Phase 2 N=126 The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) Study
Diabetic Macular Edema
Primary: Mean Change in Best Corrected Visual Acuity (BCVA) at Month 6 — 7.24; -0.43; 3.8 Mean letter change in BCVA
Phase 2 N=46 Oral Immunotherapy for Wheat Allergy
Wheat Allergy
Primary: The Percentage of Desensitized Participants as Measured by the Ability to Consume at Least 4443 mg of Wheat Protein During a 7443 mg Wheat Protein Oral Food Challenge…
Phase 1 N=1 Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study
Myelodysplastic Syndrome
Primary: Adverse Events — 1 participants
Phase 3 N=572 Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia
AtrioVentricular Nodal Reentrant Tachycardia · Supraventricular Tachycardia · Heart Disease
Primary: Chronic Effectiveness (Through 6 Months) of the Freezor Xtra Catheter for the Treatment of AVNRT Using an Endocardial Approach. — 368; 29 Participants — p=<0.0001
Phase 3 N=354 Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older
Herpes Zoster
Primary: Number of Subjects With Vaccine Response to Anti-glycoprotein E (Anti-gE) Antibodies as Determined by the Enzyme-linked Immunosorbent Assay (ELISA). — 110; 104 Subjects
N/A N=175 A Collaborative Care Program to Improve Depression Treatment in Cardiac Patients
Coronary Artery Disease · Congestive Heart Failure · Arrhythmia
Primary: Rates of Adequate Depression Treatment at Discharge — 71.9; 9.5 percentage of participants
N/A N=110 Oral Probiotics Reduce Group B Streptococci Colonization in Pregnant Women
Group B Streptococcal Infection
Primary: Number of GBS-Positive Pregnant Women Who Became GBS-Negative at Childbirth — 21; 9 Participants
N/A N=50 Application Time of Plaster-of-Paris Splint Packs Compared to Bulk Supplies Following Standard Orthopaedic Procedure
Post-operative Time Saving Techniques
Primary: Total Splint Application Time — 354; 526 seconds
N/A N=50 The Impact of Storage Techniques on Platelets Number and Function After Acute Normovolemic Hemodilution (ANH)
Cardiac Surgical Procedures
Primary: Time to Platelet Aggregation as Measured Using Collagen-epinephrine (EPI) — 260; 261 seconds